Volatility prompts Glenmark Pharma to reduce working capital cycle – interview
The India-based drugmaker aims to reduce its working capital cycle to boost cash generation amid mounting uncertainty, signalling the increasing importance of liquidity, says CFO Rajesh Desai.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts